Short answer
Incyte (INCY) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Incyte completed its acquisition of Vega Therapeutics, a wholly owned Star Therapeutics subsidiary.
Incyte 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Incyte completed its acquisition of Vega Therapeutics, a wholly owned Star Therapeutics subsidiary
- Transaction closure converts the previously announced deal into an executed strategic and financial commitment
- Acquisition details, consideration, and expected business impact are contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Completed Vega Therapeutics acquisition for $1.25B upfront, adding late-stage hematology asset VGA039
- Star Therapeutics eligible for up to $750M in sales milestones, creating substantial contingent consideration
- VGA039 in pivotal Phase 3 VIVID-6 for all VWD types, with Breakthrough Therapy, Fast Track, orphan drug and rare pediatric designations
- Potential once-monthly subcutaneous prophylaxis could replace frequent intravenous infusions for VWD patients
- Acquisition expected as one-time R&D expense in third-quarter and full-year 2026 GAAP and non-GAAP results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Incyte 8-K filings
Get the next INCY 8-K as it lands
Follow INCY for push alerts, or ask the research agent what this filing means.